CarrollDNHudsonEB.Venous thromboembolism prophylaxis conversion in nonsurgical inpatients. Ann Pharmacother2003;37:1194–6. DOI 10.1345/aph.1C509.
2.
SamamaMMCohenATDarmonJYDesjardinsLEldorAJanbonCA comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin study group. N Engl J Med1999;341: 793–800.
3.
HarenbergJSchomakerUFlosbachCW.Enoxaparin is superior to unfractionated heparin in the prevention of thromboembolic events in medical patients at increased thromboembolic risk (abstract 1767). Blood1999;94(suppl 1):399a.
4.
HillbomMSotaniemiEKFlosbachCW.Comparison of the efficacy and safety of the low-molecular-weight heparin enoxaparin with unfractionated heparin in the prevention of deep vein thrombosis in patients with acute ischemic stroke (abstract 798). Blood1999;94(suppl 1):183a.
5.
GoldhaberSZDunnKMacDougallRC.New onset of venous thromboembolism among hospitalized patients at Brigham and Women's Hospital is caused more often by prophylaxis failure than by withholding treatment. Chest2000;118:1680–4.
6.
De LissovoyGSubediP.Economic evaluation of enoxaparin as prophylaxis against venous thromboembolism in seriously ill medical patients: A US perspective. Am J Manag Care2002;8:1082–8.
